Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

Interatrial shunt (IAS) devices are emerging as a novel treatment option for patients with heart failure (HF) and mildly reduced or preserved ejection fraction (HFpEF). 1-3 Latent pulmonary vascular disease might affect the benefits of IAS devices. 1 Schuster et al. 4 hypothesized that non-invasive characterization of cardiac and pulmonary physiology by cardiac magnetic resonance (CMR) during exercise may help in patient selection for IAS. Overall, 75 patients with HFpEF who underwent rest and exercise stress right heart catheterization, echocardiography and CMR were included. Latent pulmonary vascular disease, defined as pulmonary vascular resistance during exercise stress ≥1.74 Wood units, was associated with impaired right ventricular (RV) functional reserve and diastolic filling with a consequent reduction in left ventricular cardiac index. Cardiac amyloidosisCardiac amyloidosis (CA) is associated with disproportionally elevated natriuretic peptide and troponin levels. 5,6 Vergaro et al. 7 investigated the diagnostic role of these biomarkers in 1149 patients with suspected CA who underwent a diagnostic work-up in three European centres (n = 343, derivation cohort; n = 806, validation cohort). N-terminal pro-B-type natriuretic peptide <180 ng/L and high-sensitivity troponin T (hs-TnT) <14 ng/L ruled out the diagnosis of CA, whereas hs-TnT ≥86 ng/L was found as a rule-in cut-off for CA.

show abstract

“…However, FCM is still underused in clinical practice 24 . McEwan et al 25 . conducted a cost‐effective analysis using data from five countries.…”

Section: Medical Therapymentioning

confidence: 99%

“…[20][21][22][23] However, FCM is still underused in clinical practice. 24 McEwan et al 25 conducted a cost-effective analysis using data from five countries. The authors showed that fewer hospitalizations and a shorter length of stay with FCM have a positive economic impact on healthcare systems.…”

Section: Medical Therapymentioning

confidence: 99%

March 2023 at a glance: pathophysiology, medical therapy and devices

Tomasoni

Adamo

Metra

2023

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…Iron deficiency is common among patients with HF and intravenous (IV) iron improves quality of life and outcomes in them 22–26 . A meta‐analysis including 10 randomized controlled trials and 3373 patients evaluated the impact of IV iron administration on outcome.…”

Section: Comorbiditiesmentioning

confidence: 99%

April 2023 at a glance: focus on diagnosis and comorbidities

Tomasoni

Adamo

Metra

2023

European J of Heart Fail

View full text Add to dashboard Cite

2024 update in heart failure

Beghini,

Sammartino,

Papp

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of the 2021 HF guidelines introduced new key recommendations based on the results of the last years of science. First, two drugs, sodium–glucose co‐transporter‐2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for the prevention of HF in patients with diabetic chronic kidney disease (CKD). Second, SGLT2 inhibitors are now recommended for the treatment of HF across the entire left ventricular ejection fraction spectrum. The benefits of quadruple therapy in patients with HF with reduced ejection fraction (HFrEF) are well established. Its rapid and early up‐titration along with a close follow‐up with frequent clinical and laboratory re‐assessment after an episode of acute HF (the so‐called ‘high‐intensity care’ strategy) was associated with better outcomes in the STRONG‐HF trial. Patients experiencing an episode of worsening HF might require a fifth drug, vericiguat. In the STEP‐HFpEF‐DM and STEP‐HFpEF trials, semaglutide 2.4 mg once weekly administered for 1 year decreased body weight and significantly improved quality of life and the 6 min walk distance in obese patients with HF with preserved ejection fraction (HFpEF) with or without a history of diabetes. Further data on safety and efficacy, including also hard endpoints, are needed to support the addition of acetazolamide or hydrochlorothiazide to a standard diuretic regimen in patients hospitalized due to acute HF. In the meantime, PUSH‐AHF supported the use of natriuresis‐guided diuretic therapy. Further options and most recent evidence for the treatment of HF, including specific drugs for cardiomyopathies (i.e., mavacamten in hypertrophic cardiomyopathy and tafamidis in transthyretin cardiac amyloidosis), device therapies, cardiac contractility modulation and percutaneous treatment of valvulopathies, with the recent finding from the TRILUMINATE Pivotal trial, are also reviewed in this article.

show abstract

Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

Cited by 5 publications

References 27 publications

March 2023 at a glance: pathophysiology, medical therapy and devices

March 2023 at a glance: pathophysiology, medical therapy and devices

April 2023 at a glance: focus on diagnosis and comorbidities

2024 update in heart failure

Contact Info

Product

Resources

About